Novel Antibody-Drug Conjugate Trastuzumab Botidotin Cuts Breast Cancer Progression Risk by 61% Over Standard-of-Care T-DM1

On September 11, 2026, the Journal of Clinical Oncology published final Phase 3 trial results demonstrating that a novel antibody-drug conjugate, trastuzumab botidotin, reduced the risk of disease progression or death by 61% compared to the standard-of-care therapy T-DM1 in patients with advanced HER2-positive breast cancer. The findings establish a new benchmark for second-line treatments in this aggressive cancer subtype.[2]

The KL166-III-06 trial enrolled 365 adult patients with unresectable or metastatic HER2-positive breast cancer. All participants had previously been treated with at least one trastuzumab-based regimen and a taxane chemotherapy. Patients were randomly assigned in a 1:1 ratio to receive either intravenous trastuzumab botidotin or T-DM1.[1][2]

At a median follow-up of 14.9 months, patients receiving trastuzumab botidotin achieved a median progression-free survival of 11.1 months, more than doubling the 4.4 months observed in the T-DM1 control group. The hazard ratio stood at 0.39, representing a highly statistically significant improvement in delaying disease progression.[2]

Tumor shrinkage was both more frequent and longer-lasting with the new drug. The objective response rate reached 76.9% for trastuzumab botidotin, compared to 53.0% for T-DM1. Furthermore, the median duration of response extended to 12.2 months versus just 5.7 months for the older therapy.[1][2]

Trastuzumab botidotin belongs to a rapidly advancing class of therapies known as antibody-drug conjugates. It utilizes a HER2-directed monoclonal antibody to seek out cancer cells, then delivers a highly potent cytotoxic payload—a tubulin inhibitor called Duo-5—directly inside the tumor via an enzyme-cleavable linker.[1][3]

Once internalized by the tumor cells, the Duo-5 payload is released, inducing cell cycle arrest in the G2/M phase and leading directly to tumor cell apoptosis. This targeted delivery mechanism maximizes tumor-specific killing while minimizing systemic damage to surrounding healthy tissue.[1][3]

The new therapy presented a distinct side-effect profile compared to existing treatments. Trial investigators reported that trastuzumab botidotin was associated with manageable ocular toxicity. Despite these side effects, the overall safety profile was considered favorable given the substantial extension in progression-free survival.[1][3]

While overall survival data remains immature, early trends show a 38% reduction in the risk of death favoring the new drug, with an overall survival hazard ratio of 0.62. Based on these pivotal results, the therapy recently secured approval from China's National Medical Products Administration. "We are thrilled to see our first HER2 ADC drug, trastuzumab botidotin, successfully approved for market," said Dr. Michael Ge, CEO of Kelun-Biotech. "This marks a significant advancement in the treatment of HER2-positive breast cancer."[1][2][3]